CTRI/2018/10/016039尚未招募未知
An Exploratory Study to Evaluate Surgical Outcome and Financial Burden in Patients Treated with 3D Printing Technology Assisted Surgery versus Conventional Surgery for Facial Fractures at Level 1 Trauma Centre, AIIMS, New Delhi.
All India Institute of Medical SciencesNew Delhi0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Both male and females ,
- •2.Age:18-65 years
- •3.GCS > 13
- •4.Secondary facial deformities
排除标准
- •1.Patient not giving informed consent
- •2.GCS < 13
- •3.Fresh facial Injuries
- •4.Evidence of infection with HIV/hepatitis B
- •5.Pregnancy/Breastfeeding
- •6.Underlying Systemic disorders
- •Patient on
- •ii.Immuno-modulator drugs
- •iii.Blood thinners
- •iv.Anti-Psychotic drugs
- •v.having cardiac surgeries in last 6 months
- •Uncontrolled Diabetes
- •Infection at local site
研究者
相似试验
已完成
不适用
A prospective observational study of the surgery for lung cancer in patients with low pulmonary functioPrimary lung cancer, Chronic Obstructive Lung Disease (COPD)JPRN-UMIN000013233Yokohama City University Medical Center152
招募中
Unknown
Prospective Study Evaluating The Treatment Outcomes For Localised Recurrent, Resectable Retroperitoneal LiposarcomaRetroperitoneal Liposarcoma (LPS)Cancer - Sarcoma (also see 'Bone') - soft tissueACTRN12624000554561Australia and New Zealand Sarcoma Association100
尚未招募
不适用
A study to compare success using wet and dry graft in ear surgeryCTRI/2019/02/017654JLN MEDICAL COLLEGE
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylateGastro-intestinal stromal tumour (GIST)Cancer - Other cancer typesACTRN12609000681257European Organisation for Research and Treatment of Cancer (EORTC)350
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.bowel wall cancer1001799010017998GISTNL-OMON32805European Organisation for Research in Treatment of Cancer (EORTC)60